Altered Hormone and Bioactive Lipid Plasma Profile in Rodent Models of Polycystic Ovarian Syndrome Revealed by Targeted Mass Spectrometry

October 2024 in “ bioRxiv (Cold Spring Harbor Laboratory) ”

Hannah C. Scott, Martin Philpott, G. Berridge, Zhanru Yu, Darragh P. O’Brien, Christian Becker, Cecilia Lindgren, Udo Opperman, Joerg Mueller, Martin Fritsch, Adán Pinto-Fernández, Benedikt M. Kessler

polycystic ovarian syndrome PCOS letrozole 5α-androstene-3,17-dione testosterone dihydrotestosterone dehydroepiandrosterone-sulphate allopregnanolone progesterone pregnenolone D-sphingosine 25-hydroxycholesterol leukotriene C4 4-cholesten-3-one DHT DHEA-S

Preprint — not peer reviewed. This was posted to a preprint server or data repository. It has not been through a journal's review process, and its findings may change or not hold up.

Studysummary This study examined lipid changes in rat models of polycystic ovarian syndrome, finding that letrozole and dihydrotestosterone treatments led to some lipid alterations similar to human PCOS, while other changes were unique to the models.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on biorxiv.org →

Discuss this study in the Community →

Research cited in this study

4 / 4 results

research Androgen Excess: Investigations and Management

82 citations , May 2016 in “Best Practice & Research in Clinical Obstetrics & Gynaecology”

This article outlines the clinical features, evaluation, and treatment strategies for androgen excess in polycystic ovary syndrome, highlighting important diagnostic and management approaches but reporting no new research results.

research Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome (PCOS)

4025 citations , December 2003 in “Human Reproduction”

This review discusses the evolution of diagnostic criteria for polycystic ovary syndrome and emphasizes its association with various metabolic and cardiovascular risks, but it provides no new research findings.

research Prevalence of Polycystic Ovaries in Women with Androgenic Alopecia

84 citations , November 2003 in “European journal of endocrinology”

This study found that women with androgenic alopecia had a higher prevalence of polycystic ovarian morphology and higher androgen levels compared to controls, suggesting a strong association with PCO.

research Bioavailability of Albumin-Bound Testosterone

255 citations , October 1985 in “The Journal of Clinical Endocrinology & Metabolism”

This study concluded that albumin-bound testosterone is biologically important and significantly contributes to testosterone bioavailability in women receiving spironolactone.